Join Yasmin Schlegel’s Journey Against Breast Cancer Recurrence

Beloved friends and supporters

United States, 16th Jan 2024, King NewsWireI’m a U.S. Army veteran and a survivor of Triple Negative Breast Cancer (TNBC). Diagnosed in August 2021, my journey has been one of resilience and determination. I underwent a rigorous treatment plan, enduring 5 months of intravenous chemotherapy with immunotherapy, followed by a lumpectomy in March 2022, and 30 radiation sessions in June 2022. Encouragingly, my scans in August 2022 were positive, prompting the addition of Xeloda to eliminate any residual cancer cells. I successfully completed the Xeloda treatments in February 2023.

Despite these efforts, a recent November 2023 mammogram revealed small calcifications near the surgical bed, indicating a breast cancer recurrence. To combat this setback, I am now exploring alternative treatments both within and outside the U.S. One promising option is Dendritic Cell Therapy, a groundbreaking approach in Europe.

Dendritic Cell Therapy involves utilising dendritic cells and a patient’s blood sample, combining them in a lab. After a week of incubation, the reinvigorated dendritic cells are reintroduced into the body, acting as a personalised vaccine to combat and reduce cancer recurrences.

As I embark on this new phase of treatment, I am reaching out to seek your support in making Dendritic Cell Therapy and other complementary treatments possible. Your contribution will play a crucial role in enhancing my chances of overcoming this recurrence and achieving a healthier future.

Join me in this fight against cancer, and together, let’s make a difference.

Thanks for your support.
Yasmin Schlegel

For media inquiries, please contact:

Yasmin Schlegel

Media Contact

Organization: Spotfund.



Email: Send Email

Country: United States

Release Id: 1601248921

The post Join Yasmin Schlegel’s Journey Against Breast Cancer Recurrence appeared first on King NewsWire. It is provided by a third-party content provider. King Newswire makes no warranties or representations in connection with it.

Disclaimer: The views, suggestions, and opinions expressed here are the sole responsibility of the experts. No Economy Compare journalist was involved in the writing and production of this article.

Vehement Finance News Network